{"id":8728,"date":"2024-02-20T22:32:00","date_gmt":"2024-02-20T14:32:00","guid":{"rendered":"https:\/\/flcube.com\/?p=8728"},"modified":"2024-12-22T21:55:52","modified_gmt":"2024-12-22T13:55:52","slug":"sinovent-secures-usd-97-2-million-in-series-e-financing-to-boost-clinical-trials-and-commercialization","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=8728","title":{"rendered":"Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization"},"content":{"rendered":"\n<p>Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a Series E financing round, raising RMB 700 million (USD 97.2 million). The round was co-led by Tencent Investment and Guoxin Investment, with additional contributions from Jinan Industrial Development Investment, Huakong Investment, Yuekai Securities, Sea of Stars Capital, Pudong Venture Investment, and existing investor Loyal Valley Capital, among others. The funds will be utilized to advance domestic and international clinical trials, enhance targeted therapy, anti-infection, and PROTACT technology platforms, expedite manufacturing plant operations and commercial team development, and facilitate product launches.<\/p>\n\n\n\n<p>Established in 2017, Evopoint Biosciences has a robust product pipeline that includes BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and next-generation ADCs, with therapeutic indications for tumors, multidrug-resistant bacterial infections, and metabolic diseases. Its new generation \u03b2-lactamase inhibitor, XNW4107, a broad-spectrum antibiotic resistance drug, is currently undergoing a global, multi-center Phase III study. The novel uric acid lowering drug XNW3009 has entered Phase III trials, demonstrating superior uric acid-lowering effects compared to benzbromarone and febuxostat in prior studies. Moreover, the EZH2 inhibitor XNW5004 has exhibited outstanding anti-tumor efficacy in indications such as hematomas and prostate cancer and is currently in Phase II studies.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,2896,20,1518],"class_list":["post-8728","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-evopoint-biosciences","tag-finance","tag-sinovent"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a Series E financing round, raising RMB 700 million (USD 97.2 million). The round was co-led by Tencent Investment and Guoxin Investment, with additional contributions from Jinan Industrial Development Investment, Huakong Investment, Yuekai Securities, Sea of Stars Capital, Pudong Venture Investment, and existing investor Loyal Valley Capital, among others. The funds will be utilized to advance domestic and international clinical trials, enhance targeted therapy, anti-infection, and PROTACT technology platforms, expedite manufacturing plant operations and commercial team development, and facilitate product launches.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=8728\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=8728\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-20T14:32:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-22T13:55:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8728#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8728\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization\",\"datePublished\":\"2024-02-20T14:32:00+00:00\",\"dateModified\":\"2024-12-22T13:55:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8728\"},\"wordCount\":213,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Evopoint Biosciences\",\"Finance\",\"Sinovent\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8728#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8728\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=8728\",\"name\":\"Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-02-20T14:32:00+00:00\",\"dateModified\":\"2024-12-22T13:55:52+00:00\",\"description\":\"Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a Series E financing round, raising RMB 700 million (USD 97.2 million). The round was co-led by Tencent Investment and Guoxin Investment, with additional contributions from Jinan Industrial Development Investment, Huakong Investment, Yuekai Securities, Sea of Stars Capital, Pudong Venture Investment, and existing investor Loyal Valley Capital, among others. The funds will be utilized to advance domestic and international clinical trials, enhance targeted therapy, anti-infection, and PROTACT technology platforms, expedite manufacturing plant operations and commercial team development, and facilitate product launches.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8728#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8728\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8728#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization - Insight, China&#039;s Pharmaceutical Industry","description":"Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a Series E financing round, raising RMB 700 million (USD 97.2 million). The round was co-led by Tencent Investment and Guoxin Investment, with additional contributions from Jinan Industrial Development Investment, Huakong Investment, Yuekai Securities, Sea of Stars Capital, Pudong Venture Investment, and existing investor Loyal Valley Capital, among others. The funds will be utilized to advance domestic and international clinical trials, enhance targeted therapy, anti-infection, and PROTACT technology platforms, expedite manufacturing plant operations and commercial team development, and facilitate product launches.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=8728","og_locale":"en_US","og_type":"article","og_title":"Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=8728","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-02-20T14:32:00+00:00","article_modified_time":"2024-12-22T13:55:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=8728#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=8728"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization","datePublished":"2024-02-20T14:32:00+00:00","dateModified":"2024-12-22T13:55:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=8728"},"wordCount":213,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Evopoint Biosciences","Finance","Sinovent"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=8728#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=8728","url":"https:\/\/flcube.com\/?p=8728","name":"Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-02-20T14:32:00+00:00","dateModified":"2024-12-22T13:55:52+00:00","description":"Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a Series E financing round, raising RMB 700 million (USD 97.2 million). The round was co-led by Tencent Investment and Guoxin Investment, with additional contributions from Jinan Industrial Development Investment, Huakong Investment, Yuekai Securities, Sea of Stars Capital, Pudong Venture Investment, and existing investor Loyal Valley Capital, among others. The funds will be utilized to advance domestic and international clinical trials, enhance targeted therapy, anti-infection, and PROTACT technology platforms, expedite manufacturing plant operations and commercial team development, and facilitate product launches.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=8728#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=8728"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=8728#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8728"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8728\/revisions"}],"predecessor-version":[{"id":19358,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8728\/revisions\/19358"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}